Norve\u00e7\u2019te ger\u00e7ekle\u015ftirilen yeni bir ara\u015ft\u0131rma, d\u00fc\u015f\u00fck doz aspirin kullan\u0131m\u0131n\u0131n epitelyal over (yumurtal\u0131k) kanseri (EOC) hastalar\u0131nda sa\u011fkal\u0131m oranlar\u0131n\u0131 art\u0131rma potansiyeline dair \u00f6nemli bulgular sunuyor. BMC Cancer dergisinde yay\u0131mlanan bu kapsaml\u0131 kay\u0131t tabanl\u0131 kohort \u00e7al\u0131\u015fmas\u0131, 2004-2018 y\u0131llar\u0131 aras\u0131nda invaziv EOC tan\u0131s\u0131 alan d\u00f6rt binden fazla kad\u0131n\u0131n medikal verilerini analiz ederek aspirin ve non-aspirin non-steroid anti-inflamatuar ila\u00e7lar\u0131n (NA-NSAID) hastal\u0131k sonras\u0131 sa\u011fkal\u0131ma etkisini de\u011ferlendirdi. \u00c7al\u0131\u015fma, kanser tedavisinde yan etkileri azaltabilen ve hayatta kalma \u015fans\u0131n\u0131 art\u0131rabilecek yeni yakla\u015f\u0131mlar\u0131n aranmas\u0131na katk\u0131 sa\u011fl\u0131yor.<\/p>\n
Over kanseri, \u00f6zellikle erken evrelerde belirgin semptom g\u00f6stermemesi ve etkili bir erken tan\u0131 y\u00f6nteminin bulunmamas\u0131 nedeniyle genellikle ileri evrede te\u015fhis ediliyor. Bu durum, be\u015f y\u0131ll\u0131k sa\u011fkal\u0131m oranlar\u0131n\u0131n halen olduk\u00e7a d\u00fc\u015f\u00fck kalmas\u0131na neden oluyor. Son y\u0131llarda uygulanan tedavi y\u00f6ntemlerindeki geli\u015fmelere ra\u011fmen hastal\u0131\u011f\u0131n ilerlemesi ve tedaviye diren\u00e7 gibi problemler nedeniyle ek destek tedavilerine ihtiya\u00e7 duyuluyor. Aspirin ve di\u011fer NSAID\u2019lerin anti-inflamatuar etkileri, kanser h\u00fccrelerinin ilerlemesini yava\u015flatma potansiyeli nedeniyle bir\u00e7ok bilim insan\u0131 taraf\u0131ndan ara\u015ft\u0131r\u0131l\u0131yor; ancak mevcut epidemiyolojik \u00e7al\u0131\u015fmalar\u0131n sonu\u00e7lar\u0131 farkl\u0131 ve kimi zaman \u00e7eli\u015fkili oldu.<\/p>\n
Norve\u00e7li ara\u015ft\u0131rmac\u0131lar, bu \u00e7al\u0131\u015fmada aspirin ve NA-NSAID kullan\u0131m\u0131n\u0131 hem sabit (fixed) hem de zamanla de\u011fi\u015fen (time-varying) modellerle analiz etti. Sabit modelde, tan\u0131 sonras\u0131 ilk 305 g\u00fcn i\u00e7inde ila\u00e7 kullanan ve kullanmayan ki\u015filer ayr\u0131 kategorilere ayr\u0131ld\u0131. \u00d6te yandan zamanla de\u011fi\u015fen model, ila\u00e7 kullan\u0131m\u0131n\u0131n tan\u0131 sonras\u0131 de\u011fi\u015fkenli\u011fini ve devaml\u0131l\u0131\u011f\u0131n\u0131 yans\u0131tarak kullan\u0131c\u0131lar\u0131n mevcut, ge\u00e7mi\u015f ya da hi\u00e7 kullanmam\u0131\u015f olma durumunu hesaba katt\u0131. Ayr\u0131ca, ilac\u0131n toplam kullan\u0131ld\u0131\u011f\u0131 miktar, Tan\u0131mlanm\u0131\u015f G\u00fcnl\u00fck Doz (Defined Daily Dose \u2013 DDD) yard\u0131m\u0131yla de\u011ferlendirildi. \u00c7al\u0131\u015fma, ilac\u0131n sadece tan\u0131 sonras\u0131 de\u011fil, tan\u0131 \u00f6ncesindeki kullan\u0131m\u0131n\u0131n da sa\u011fkal\u0131ma etkisini inceleyerek kullan\u0131m zamanlamas\u0131n\u0131n \u00f6nemini ortaya koymaya \u00e7al\u0131\u015ft\u0131.<\/p>\n
\u00c7ok de\u011fi\u015fkenli Cox orant\u0131sal risk modelleri kullan\u0131larak yap\u0131lan analizler, ilac\u0131n neden oldu\u011fu \u00f6l\u00fcm riskini kar\u015f\u0131la\u015ft\u0131rmal\u0131 \u015fekilde sunarken, bak\u0131m\u0131n bir\u00e7ok potansiyel kar\u0131\u015ft\u0131r\u0131c\u0131 fakt\u00f6r\u00fcn\u00fc g\u00f6z \u00f6n\u00fcne ald\u0131. Ayr\u0131ca ara\u015ft\u0131rmac\u0131lar, sonu\u00e7lar\u0131n klinik olarak daha anla\u015f\u0131l\u0131r olmas\u0131 ad\u0131na rezerve edilmi\u015f ortalama sa\u011fkal\u0131m s\u00fcresi (Restricted Mean Survival Time \u2013 RMST) analizlerini uygulad\u0131. Bu sayede, aspirin kullan\u0131c\u0131lar\u0131 ve hi\u00e7 kullanmayanlar aras\u0131ndaki sa\u011fkal\u0131m s\u00fcresi fark\u0131 be\u015f y\u0131l \u00fczerinden \u00f6l\u00e7\u00fcld\u00fc.<\/p>\n
\u00c7al\u0131\u015fman\u0131n \u00f6nemli bulgular\u0131ndan biri, tan\u0131dan sonraki erken d\u00f6nemde sabit modelle de\u011ferlendirilen aspirin kullan\u0131m\u0131n\u0131n sa\u011fkal\u0131m \u00fczerinde anlaml\u0131 bir etkisinin g\u00f6zlenmemesi oldu. Ancak zamanla de\u011fi\u015fen modelde, tan\u0131 sonras\u0131 g\u00fcncel aspirin kullan\u0131m\u0131n\u0131n, over kanserine ba\u011fl\u0131 \u00f6l\u00fcm riskini %32 oran\u0131nda azaltt\u0131\u011f\u0131 ve bu etkinin istatistiksel olarak anlaml\u0131 oldu\u011fu g\u00f6r\u00fcld\u00fc (Risk Oran\u0131 0.68, %95 G\u00fcven Aral\u0131\u011f\u0131 0.57-0.81). Bu da aspirin kullan\u0131m\u0131 ile sa\u011fkal\u0131m aras\u0131nda g\u00fc\u00e7l\u00fc ve olumlu bir ili\u015fki oldu\u011funu g\u00f6steriyor.<\/p>\n
Dahas\u0131, aspirin kullan\u0131m\u0131n\u0131n doz ve s\u00fcreye ba\u011fl\u0131 olarak sa\u011fkal\u0131m \u00fczerinde artan fayda sa\u011flad\u0131\u011f\u0131 belirlendi. Yani, daha y\u00fcksek k\u00fcm\u00fclatif dozda aspirin kullanan hastalar daha uzun sa\u011fkal\u0131m elde etti. Bu sonu\u00e7, aspirin etken maddesinin biyolojik etkinli\u011fine a\u00e7\u0131kl\u0131k getirirken, d\u00fczenli ve uzun s\u00fcreli kullan\u0131m\u0131n tedavi ba\u015far\u0131s\u0131nda kritik olabilece\u011fini i\u015faret ediyor. Oysa NA-NSAID\u2019lerin sa\u011fkal\u0131ma etkileri daha de\u011fi\u015fken ve tutars\u0131z g\u00f6r\u00fcld\u00fc; bu durum ila\u00e7lar\u0131n etki mekanizmalar\u0131ndaki farkl\u0131l\u0131klar ya da hastalar\u0131n kullan\u0131m al\u0131\u015fkanl\u0131klar\u0131ndan kaynaklanabilir.<\/p>\n
\u00d6n tan\u0131 d\u00f6neminde aspirin ya da NA-NSAID kullan\u0131lan hastalarda ise herhangi bir sa\u011fkal\u0131m avantaj\u0131 tespit edilmedi. Bu da aspirin kullan\u0131m\u0131n\u0131n kanser tan\u0131s\u0131n\u0131 takip eden erken evrelerde \u00f6nem ta\u015f\u0131d\u0131\u011f\u0131n\u0131, \u00f6nceden kullan\u0131lan aspirinlerin hastal\u0131k seyrini etkilemedi\u011fini d\u00fc\u015f\u00fcnd\u00fcr\u00fcyor. Bu bulgu, aspirin etkisinin t\u00fcm\u00f6r mikro\u00e7evresinde ve kalan t\u00fcm\u00f6r h\u00fccrelerine kar\u015f\u0131 erken post-diagnostik d\u00f6nemde ortaya \u00e7\u0131kt\u0131\u011f\u0131 hipotezini g\u00fc\u00e7lendiriyor.<\/p>\n
\u00c7al\u0131\u015fman\u0131n neden-sonu\u00e7 ili\u015fkisini g\u00fc\u00e7lendiren di\u011fer bir g\u00f6stergesi, hem hastal\u0131\u011fa spesifik hem de genel sa\u011fkal\u0131m analizlerinde benzer e\u011filimlerin g\u00f6r\u00fclmesi oldu. RMST analizlerine g\u00f6re, tan\u0131 sonras\u0131 aspirin kullanan hastalar, kullanmayanlara k\u0131yasla be\u015f y\u0131ll\u0131k takip s\u00fcresi boyunca ortalama 2,67 ay daha fazla ya\u015fad\u0131. Kanser tedavisinde bu t\u00fcr nispeten k\u00fc\u00e7\u00fck s\u00fcre uzatmalar\u0131 bile, \u00f6zellikle agresif ve hayatta kalma s\u00fcresi k\u0131s\u0131tl\u0131 olan over kanseri i\u00e7in anlaml\u0131 kabul ediliyor.<\/p>\n
Aspirin\u2019in anti-kanser etkileri; inflamasyonun bask\u0131lanmas\u0131, siklooksijenaz (COX) enzimlerinin inhibisyonu ve bunun sonucunda prostaglandin sentezinin azalmas\u0131 gibi mekanizmalarla a\u00e7\u0131klanabiliyor. Prostaglandinlerin t\u00fcm\u00f6r b\u00fcy\u00fcmesi, t\u00fcm\u00f6r i\u00e7i yeni damar olu\u015fumu ve metastaz\u0131nda \u00f6nemli rol\u00fc bulunuyor. Ek olarak aspirin\u2019in kan pulcuklar\u0131n\u0131n (platelet) fonksiyonunu engellemesi, metastatik h\u00fccrelerin yay\u0131l\u0131m\u0131n\u0131 azaltabilir. Bu biyolojik veriler, aspirin\u2019in \u00e7e\u015fitli kanser t\u00fcrlerindeki koruyucu ve adjuvan etkilerine dair g\u00fc\u00e7l\u00fc bir zemin olu\u015fturuyor.<\/p>\n
Bununla birlikte, b\u00fcy\u00fck hasta say\u0131s\u0131 ve ger\u00e7ek d\u00fcnya verilerinin kullan\u0131ld\u0131\u011f\u0131 g\u00fc\u00e7l\u00fc metodolojisine kar\u015f\u0131n, \u00e7al\u0131\u015fma g\u00f6zlemsel nitelikte oldu\u011fu i\u00e7in t\u00fcm kar\u0131\u015ft\u0131r\u0131c\u0131 fakt\u00f6rleri tamamen kontrol edemedi ve do\u011frudan nedensellik olu\u015fturmak m\u00fcmk\u00fcn olmad\u0131. Ara\u015ft\u0131rmac\u0131lar, aspirinin adjuvan tedavide etkinli\u011finin kesinle\u015fmesi i\u00e7in randomize kontroll\u00fc \u00e7al\u0131\u015fmalarla (RCT) investige edilmesini \u00f6neriyor. \u00d6zellikle dozland\u0131rma, kullan\u0131m zamanlamas\u0131 ve hangi hasta alt gruplar\u0131nda en y\u00fcksek faydan\u0131n sa\u011flanaca\u011f\u0131 \u00fczerinde durulmal\u0131.<\/p>\n
Bu \u00e7al\u0131\u015fma, d\u00fc\u015f\u00fck maliyetli ve eri\u015filebilir bir ila\u00e7 olan aspirin\u2019in kanser tedavisinde yeniden kullan\u0131m\u0131 konusundaki global tart\u0131\u015fmalara yeni ivme kazand\u0131r\u0131yor. Asgari yan etkilerle hastalar\u0131n tedaviye ek fayda sa\u011flamas\u0131, toplum sa\u011fl\u0131\u011f\u0131 a\u00e7\u0131s\u0131ndan ciddi kazan\u0131mlar vaat ediyor. D\u00fc\u015f\u00fck doz aspirin ile \u00f6zellikle over kanserinde inflamasyonun hedeflenmesi, tedavi ba\u015far\u0131s\u0131n\u0131 art\u0131ran yenilik\u00e7i bir yakla\u015f\u0131m olabilir.<\/p>\n
Ara\u015ft\u0131rman\u0131n sonu\u00e7lar\u0131 ayr\u0131ca kronik inflamasyonun over kanserinin ilerlemesindeki rol\u00fcn\u00fc vurguluyor. Bu ba\u011flamda, inflamatuar yollar\u0131n farmakolojik hedeflenmesi ve aspirin gibi ajanlar\u0131n hastal\u0131k s\u00fcrecini yava\u015flatmak ya da tedavi direncini k\u0131rmak i\u00e7in kullan\u0131lmas\u0131 anlaml\u0131 bir tedavi stratejisi olarak \u00f6ne \u00e7\u0131k\u0131yor.<\/p>\n
Sonu\u00e7ta, mevcut bulgular istatiksel ili\u015fkilerin \u00f6tesinde, klinik hayatta ger\u00e7ek anlamda fayda sa\u011flamaya d\u00f6n\u00fck umut veriyor. Onkoloji prati\u011finde d\u00fc\u015f\u00fck doz aspirin tedavisinin yer almas\u0131 ile d\u00fcnya genelinde binlerce hastan\u0131n ya\u015fam s\u00fcresi ve ya\u015fam kalitesi artabilir. Bu durum \u00f6zellikle geli\u015fmekte olan \u00fclkelerde, ileri d\u00fczey tedavilere eri\u015fimin s\u0131n\u0131rl\u0131 oldu\u011fu co\u011frafyalarda b\u00fcy\u00fck \u00f6nem ta\u015f\u0131yor.<\/p>\n
Gelecekte aspirin\u2019in kemoterapi ve hedefe y\u00f6nelik ajanlarla etkile\u015fimleri, onkoloji hastalar\u0131ndaki g\u00fcvenlik profilinin detayl\u0131 ara\u015ft\u0131r\u0131lmas\u0131 ve hasta uyumu dinamikleri \u00fczerine \u00e7al\u0131\u015fmalar kritik \u00f6nem kazanacak. Ayr\u0131ca, aspirin yan\u0131t\u0131n\u0131 \u00f6ng\u00f6ren molek\u00fcler biyobelirte\u00e7lerin tespiti, tedaviyi ki\u015fiselle\u015ftirmek ve maksimum fayday\u0131 sa\u011flamak a\u00e7\u0131s\u0131ndan yeni ufuklar a\u00e7acakt\u0131r.<\/p>\n
Norve\u00e7li ara\u015ft\u0131rmac\u0131lar\u0131n sundu\u011fu bu de\u011ferli \u00e7al\u0131\u015fma, epitelyal over kanseri hastalar\u0131nda aspirin\u2019in hayatta kal\u0131m \u00fczerindeki olumlu etkisini anlamam\u0131zda d\u00f6n\u00fcm noktas\u0131 niteli\u011finde yer tutuyor. Tedavide zamanlama ve dozun ba\u015far\u0131y\u0131 etkileyen temel fakt\u00f6rler oldu\u011fu net bir bi\u00e7imde ortaya kondu. Gelecekte yap\u0131lacak kontrol gruplu klinik ara\u015ft\u0131rmalar, mevcut paradigmalar\u0131 de\u011fi\u015ftirerek, uygun dozda aspirin uygulamas\u0131n\u0131 standart tedaviye entegre etme yolunu a\u00e7abilir. Kanserle m\u00fccadelede ya\u015fam\u0131 uzatan ve maliyeti d\u00fc\u015f\u00fck bu yakla\u015f\u0131m, kanser alan\u0131ndaki yenilik\u00e7i tedavi stratejilerinin \u00f6nemli bir par\u00e7as\u0131 olma potansiyeline sahip.<\/p>\n
—<\/p>\n
Ara\u015ft\u0131rma Konusu<\/strong>: Epitelyal over kanseri hastalar\u0131nda d\u00fc\u015f\u00fck doz aspirin ve non-aspirin NSAID kullan\u0131m\u0131 sonras\u0131 sa\u011fkal\u0131m \u00fczerindeki etkilerin incelenmesi.<\/p>\n Makale Ba\u015fl\u0131\u011f\u0131<\/strong>: Low-dose aspirin and non-aspirin non-steroidal anti-inflammatory drugs and epithelial ovarian cancer survival: a registry-based cohort study in Norway.<\/p>\n Web References<\/strong>: https:\/\/doi.org\/10.1186\/s12885-025-14168-y<\/p>\n Doi Referans<\/strong>: https:\/\/doi.org\/10.1186\/s12885-025-14168-y<\/p>\n Resim Credits<\/strong>: Scienmag.com<\/p>\n Anahtar Kelimeler<\/strong>: adjuvan tedaviler, epitelyal over kanseri, d\u00fc\u015f\u00fck doz aspirin, NSAID, inflamasyon, sa\u011fkal\u0131m oranlar\u0131, kohort analizi, Norve\u00e7 kanser \u00e7al\u0131\u015fmas\u0131, post-diagnostik ila\u00e7 kullan\u0131m\u0131, kanser progresyonu, hedefe y\u00f6nelik tedavi, over kanseri sa\u011fkal\u0131m\u0131<\/p>\n","protected":false},"excerpt":{"rendered":" Norve\u00e7\u2019te ger\u00e7ekle\u015ftirilen yeni bir ara\u015ft\u0131rma, d\u00fc\u015f\u00fck doz aspirin kullan\u0131m\u0131n\u0131n epitelyal over (yumurtal\u0131k) kanseri (EOC) hastalar\u0131nda sa\u011fkal\u0131m oranlar\u0131n\u0131 art\u0131rma potansiyeline dair \u00f6nemli bulgular sunuyor. BMC Cancer dergisinde yay\u0131mlanan bu kapsaml\u0131 kay\u0131t tabanl\u0131 kohort \u00e7al\u0131\u015fmas\u0131, 2004-2018 y\u0131llar\u0131 aras\u0131nda invaziv EOC tan\u0131s\u0131 alan d\u00f6rt binden fazla kad\u0131n\u0131n medikal verilerini analiz ederek aspirin ve non-aspirin non-steroid anti-inflamatuar ila\u00e7lar\u0131n (NA-NSAID)…<\/p>\n","protected":false},"author":1,"featured_media":4365,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_wpan_schema_json_ld":"","_wpan_ai_seo_metadata":"","_wpan_ai_seo_status":"","_wpan_ai_seo_policy":"","_wpan_ai_seo_faq_block":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[28],"tags":[4404,4405,4408,4406,4407],"tmauthors":[],"class_list":{"0":"post-4364","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-kanser","8":"tag-aspirin-kullanimi-epitelyal-over-kanseri-sagkalimi","9":"tag-non-steroid-anti-inflamatuar-ilaclar-over-kanseri-tedavisi","10":"tag-norvec-kohort-calismasi-over-kanseri","11":"tag-over-kanseri-erken-evre-tani-ve-sagkalim-oranlari","12":"tag-over-kanseri-hastalarinda-aspirin-dozaj-etkileri"},"jetpack_featured_media_url":"https:\/\/haber360.com\/wp-content\/uploads\/2025\/04\/Aspirin-ve-NSAID8217lerin-Over-Kanseri-Sagkalimi-1746016162.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/4364","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/comments?post=4364"}],"version-history":[{"count":0,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/4364\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media\/4365"}],"wp:attachment":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media?parent=4364"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/categories?post=4364"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tags?post=4364"},{"taxonomy":"tmauthors","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tmauthors?post=4364"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}